The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Lack of efficacy of adjuvant lapatinib in HER2-negative breast cancer (HER2–ve BC): Analysis of patients in the TEACH trial.
Yanin Chavarri Guerra
No relevant relationships to disclose
Arlene Chan
Research Funding - Amgen
Dianne M. Finkelstein
Consultant or Advisory Role - Amgen; Johnson & Johnson
Valorie F. Chan
No relevant relationships to disclose
Vernon J. Harvey
Honoraria - Roche; Sanofi
Research Funding - Roche
Keun Seok Lee
No relevant relationships to disclose
Minish Mahendra Jain
No relevant relationships to disclose
Katarina Petrakova
No relevant relationships to disclose
Vinod Raina
No relevant relationships to disclose
Binghe Xu
No relevant relationships to disclose
Henry Gomez
No relevant relationships to disclose
Erica Rappold
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Tomomi Kaneko
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Yingjie Huang
Employment or Leadership Position - GlaxoSmithKline
Paul E. Goss
Honoraria - Pfizer